Ocuphire Pharma Completes Enrollment for Mid-Stage Trial of Combination Therapy for Eye Disorder Presbyopia
08:09 AM EDT, 05/12/2021 (MT Newswires) -- Ocuphire Pharma (OCUP) said Wednesday it has completed the enrollment in a phase 2 trial of a combination kit of Nyxol and low-dose pilocarpine as a potential treatment option for presbyopia, or the gradual loss of the eye's ability to focus on nearby objects.
The trial, which has enrolled 150 subjects at 17 US sites, will assess the efficacy and safety of the investigational combination therapy.
Topline results from the trial are expected by the end of Q2, according to a statement.
Price: 4.3300, Change: 0.00, Percent Change: 0.00